Abstract
Metastatic pancreatic cancer leads to a fatal outcome, with a median progression-free survival of approximately six months when utilizing the most successful combination of chemotherapeutic regimens. When drug resistance develops, it facilitates an increase in primary tumor growth and new and growing metastases. Patients inevitably and quickly succumb to their disease and die. Notably, chemotherapy has an unintended impact on the development of drug resistance through the enhancement of EMT development and the enrichment of cancer stem cells (CSC). Recent report discovered that neuraminidase-1 (Neu-1) regulates EMT induction, angiogenesis, and cellular proliferation by the activation of several receptor tyrosine kinases. Here, the continual therapeutic inhibition of Neu-1 through intravenous administration of oseltamivir phosphate (OP) and aspirin (ASA) alongside GEM treatment significantly inhibits tumor progression, crucial compensatory signaling pathways, EMT program, CSC, and metastasis progression in a preclinical RAG2xCy double mutant BALB/c mouse model of human PANC-1 pancreatic cancer. The tumorigenic and metastatic potential of the xenotumors from the animals treated with the experimental protocols were significantly ablated when transferred into the mammary fat pads of NSG (NOD SCID gamma) branded mice. Keywords: pancreatic cancer; chemoresistance; drug repurposing; EMT.
Keywords
Publication details
- DOI
- 10.53539/squjs.splisspp34-44
- Journal
- Sultan Qaboos University Journal for Science, 29(2), 34-44
- Publisher
- Sultan Qaboos University
- Open access
- Gold open access
- License
- CC BY-ND 4.0
Cite this article
APA 7
Aldbai, R., Baghaie, L., Bunsick, D. A., Aucoin, E. B., Li, Y., Ghokasian, D., & Szewczuk, M. R. (2024). Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer. Sultan Qaboos University Journal for Science, 29(2), 34-44. https://doi.org/10.53539/squjs.splisspp34-44
MLA 9
Aldbai, Rashelle, et al. "Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer." Sultan Qaboos University Journal for Science, vol. 29, no. 2, 2024, pp. 34-44. https://doi.org/10.53539/squjs.splisspp34-44.
Chicago (author–date)
Aldbai, Rashelle, Leili Baghaie, David A. Bunsick, Emilyn B. Aucoin, Yunfan Li, Daniella Ghokasian, and Myron R. Szewczuk. 2024. "Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer." Sultan Qaboos University Journal for Science 29 (2): 34-44. https://doi.org/10.53539/squjs.splisspp34-44.
Harvard
Aldbai, R., Baghaie, L., Bunsick, D. A., Aucoin, E. B., Li, Y., Ghokasian, D. and Szewczuk, M. R. (2024) 'Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer', Sultan Qaboos University Journal for Science, 29(2), pp. 34-44. doi:10.53539/squjs.splisspp34-44.
Vancouver
Aldbai R, Baghaie L, Bunsick DA, Aucoin EB, Li Y, Ghokasian D, et al. Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer. Sultan Qaboos University Journal for Science. 2024;29(2):34-44. doi:10.53539/squjs.splisspp34-44
IEEE
R. Aldbai, L. Baghaie, D. A. Bunsick, E. B. Aucoin, Y. Li, D. Ghokasian, and M. R. Szewczuk, "Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer," Sultan Qaboos University Journal for Science, vol. 29, no. 2, pp. 34-44, 2024, doi: 10.53539/squjs.splisspp34-44.